sars-cov-in-2

SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication.

SARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.

SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

SARS-CoV-2 Mpro-IN-2 is a selective SARS-CoV-2M pro inhibitor with an IC50 value of 0.40 μM.SARS-CoV-2 Mpro-IN-2 has good antiviral activity and can be used to study COVID-19.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay. It improves bioavailability and half-life when administered orally and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.057 μM [1].

SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is critical for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.

Compound 3h, also known as SARS-CoV-2 3CLpro-IN-17, is a selective inhibitor of the SARS-CoV-2 3CL protease, demonstrating an IC50 of 0.322 μM [1].

SARS-CoV-2-IN-55 (compound 65) is a SARS-CoV-2 inhibitor with low cytotoxicity, characterized by an IC50 of 0.3 μM, and acts through direct interaction with VSV-S pseudoparticles [1].

SARS-CoV-2 3CLpro-IN-19 (Compound C5a), a non-covalent, non-peptide inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibits potent in vitro activity with an IC50 of 0.7 μM. It demonstrates broad-spectrum efficacy against infection by Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) in human cells, with EC50 values ranging from 30-69 nM [1].

SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active inhibitor of SARS-CoV-2 3CLpro, demonstrating potent anti-SARS-CoV-2 properties with an EC50 of 0.18 μM and exhibits minimal cytotoxicity, having a CC50 greater than 50 μM, in Vero E6 cells [1].

SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 has antiviral activity and inhibits SARS-CoV-2 by inhibiting SKP2 protein and stabilizing BECN1.

SARS-CoV-2-IN-29 disodium, a diphosphate ester featuring a benzene system and molecular tweezers architecture, demonstrates antiviral efficacy by targeting SARS-CoV-2 with half-maximal inhibitory concentrations (IC50s) of 1.5 μM for virus activity and 1.6 μM for spike pseudoparticle transduction. Additionally, it disrupts liposomal membranes, evidenced by a half-maximal effective concentration (EC50) of 3.0 μM [1].

SARS-CoV-2-IN-30, a two-armed diphosphate ester featuring a benzene system and molecular tweezers, demonstrates antiviral properties, achieving IC50 values of 0.6 μM against SARS-CoV-2 activity and 6.9 μM for spike pseudoparticle transduction. Additionally, it disrupts liposomal membranes with an EC50 of 6.9 μM [1].

SARS-CoV-2-IN-30 disodium, a benzene-system-based two-armed diphosphate ester featuring molecular tweezers, demonstrates antiviral efficacy, with IC50 values of 0.6 μM against SARS-CoV-2 and 6.9 μM for spike pseudoparticle transduction, respectively. Additionally, it disrupts liposomal membranes, evidenced by an EC50 of 6.9 μM [1].

SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.

SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS-CoV-2 3CLpro with antiviral, antibacterial, and antifungal properties.

SARS-CoV-2-IN-25 (Compound CP026) disodium, a potent inhibitor of SARS-CoV-2 spike pseudoparticle transduction, demonstrates significant efficacy with an IC50 value of 1.6 μM. It also effectively inhibits enveloped viruses and liposomes, highlighting its broad-spectrum antiviral potential.

SARS-CoV-2-IN-23 disodium, a medium-length molecular tweezer and two-armed diphosphate ester, demonstrates antiviral properties by inhibiting SARS-CoV-2 activity and spike pseudoparticle transduction with IC50 values of 8.2 μM and 2.6 μM, respectively. Additionally, it disrupts liposomal membranes with an EC50 of 4.4 μM [1].

SARS-CoV-2-IN-28 disodium, a diphosphate ester featuring a C7 alkyl chain and extended-length molecular tweezers, demonstrates antiviral efficacy by showing IC50 values of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and spike pseudoparticle transduction, respectively. Additionally, it disrupts liposomal membranes with an EC50 of 4.4 μM [1].

Compound 8h, also known as SARS-CoV-2-IN-43, is a powerful inhibitor effective in obstructing the replication of SARS-CoV-2, exhibiting significant antiviral activity [1].

SARS-CoV-2-IN-57 (compound (+)-R-26) is a potent SARS-CoV-2 inhibitor with an IC50 of 80 nM, and shows high affinity for the Sigma Receptor, with Kis of 13.6 nM (S1R) and 14.4 nM (S2R) [1].

SARS-CoV-2-IN-18 (Compound 26) is a powerful inhibitor of the SARS-CoV-2 3C-like protease, with an IC50 of 45 nM [1].

SARS-CoV-2-IN-82 (compound A) acts as an inhibitor of the Programmed-1 ribosomal frameshift (-1 PRF) in SARS-CoV-2 [1].

SARS-CoV-2-IN-62 (Compound R3b) effectively inhibits SARS-CoV-2 replication in Vero E6 and Calu-3 cells, demonstrating low cytotoxicity with EC50 values of 2.97 μM and 3.82 μM, respectively [1].

SARS-CoV-2-IN-64 (compound 9), derived from chenodeoxycholic acid, is a potent inhibitor of the SARS-CoV-2 spike glycoprotein [1].

SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair, demonstrating significant research potential for SARS-CoV-2 disease.

SARS-CoV-2 nsp3-IN-1 (Compound 15c) exhibits significant selectivity for coronavirus macrodomains, particularly SARS-CoV-2 Mac1, and can inhibit Mac1 ADP-ribosylhydrolase activity with an IC50 of 6.1 μM [1].

SARS-CoV-2-IN-6 is an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 73 nM.

SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective small-molecule inhibitor of nsp13 helicase, inhibiting the ssDNA+ ATPase activity of nsp13 with an IC50 of 57 μM, and providing a broad-spectrum antiviral effect.

SARS-CoV-2-IN-17 (Compound 16) is a highly effective inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro), demonstrating potent antiviral activity with an EC50 value of 2.18 μM and binding to NPro with a low Kd value of 7.82 μM, underscoring its potency as a NPro ligand [1].

SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus inhibitor with an IC50 of 16.96 μM.

SARS-CoV-2 nsp13-IN-2 (Compound C2) is a small molecule inhibitor targeting the SARS-CoV-2 non-structural protein 13 (nsp13), specifically acting on the nsp13 ssDNA+ATPase with an IC50 of 42 μM.

SARS-CoV-2 3CLpro-IN-10(5d) is a potent inhibitor of the SARS-CoV-2 3CL protease with an IC50 value of 190 nM and demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 790 nM for SARS-CoV-1 and 70 nM for MERS-CoV.

SARS-CoV MPro-IN-2 effectively inhibits the SARS-CoV-2 main protease (M pro), crucial for the virus's replication and transcription in host cells, with an IC50 value of 72.07 nM. Given its significant role in processing viral polyproteins, M pro is regarded as a key target in drug discovery efforts. Consequently, SARS-CoV MPro-IN-2 holds promise for COVID-19 research.

SARS-CoV-2 Mpro-IN-5 is a dual inhibitor targeting Main Protease (M Pro) and Cathepsin L (CatL) with IC50 values of 1800 nM and 145 nM, respectively. This compound demonstrates antiviral activity by inhibiting SARS-CoV-2 replication in hACE2 expressing A549 cells, with an IC50 value of 14.7 nM.

ARS-CoV-2-IN-53 (Compd 5d) shows an inhibitory effect on SARS-CoV-2 replication with an EC50 value of 14.3 μM and exhibits significant antiviral activity against human coronavirus 229E (HCoV-229E) [1].

SARS-CoV-2 Mpro-IN-10 (27h) is a potent inhibitor of the Mpro enzyme, with IC50 and EC50 values of 10.9 nM and 43.6 nM, respectively. It is used in research on the SARS-CoV-2 virus [1].

SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor exhibiting antiviral activity, with an IC50 of 0.7 μM in Vero E6 cells [1].

SARS-CoV-2-IN-49 acts as an irreversible covalent inhibitor targeting the main protease of SARS-CoV-2 [1].

SARS-CoV-2-IN-50 (Compound X77C) is a potent inhibitor of the SARS-CoV-2 main protease (M^pro), demonstrating high affinity for the enzyme's catalytic site [1].

SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent targeting SARS-CoV-2, demonstrating an EC50 of 18 μM and specifically inhibiting the SARS-CoV-2 main protease (Mpro) with an IC50 of 0.35 μM [1].

SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting significant anti-coronavirus activity with an IC50 value of 21 nM [1].

SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, with IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme (3CLpro), making it an attractive candidate for intervention strategies and holds significant promise in the development of specific antivirals against SARS-CoV-2.

SARS-CoV-2-IN-31 is a potent inhibitor of COVID-19 with excellent to mild activity (IC50: 28.84-38.36 μM) against various cancer cell lines, making it useful in cancer research.

SARS-CoV-2-IN-23, a two-armed diphosphate ester and medium-length molecular tweezers, displays antiviral properties, demonstrating IC50 values of 8.2 μM against SARS-CoV-2 activity and 2.6 μM for spike pseudoparticle transduction. Additionally, it induces liposomal membrane disruption with an EC50 value of 4.4 μM [1].

SARS-CoV-2-IN-27 disodium, a diphosphate ester featuring a C6 alkyl chain and molecular tweezers of extended length, demonstrates antiviral efficacy by achieving IC50 values of 1.0 μM against SARS-CoV-2 activity and 1.7 μM for spike pseudoparticle transduction. Additionally, it disrupts liposomal membranes, displaying an EC50 value of 6.5 μM [1].

SARS-CoV-2 nsp14-IN-2 is a potent inhibitor of SARS-CoV-2 Nsp14 methyltransferase (IC50: 0.093 μM) with potential applications in COVID-19 studies.